Orchid Pharma
Orchid Pharma (ORCHPHARMA) share price was ₹865.00 at the 28 Oct 2026 close; market capitalisation ₹5,180 Cr; P/E (TTM) 411.90; sector Healthcare. The share price rose 22.9% over the year to 28 Oct 2026 (adjusted for splits and bonuses). In the Jun 2026 quarter, revenue rose 15.6% year on year to ₹304.17 Cr and net profit was ₹3.22 Cr, against −₹5.69 Cr a year earlier (compared with Jun 2025). Promoters held 74.45% of Orchid Pharma in Sep 2026, up 4.61 percentage points from Jun 2026. Its Tapetide Score is 36/100 (Poor) as of 28 Oct 2026.
Key Fundamentals
MicrocapPharmaceuticals & BiotechnologyHealthcarePrice-based figures as of 28 Oct 2026, 15:31 IST · EPS basis: Consolidated · TTM
Peer Comparison
Healthcare › Pharmaceuticals
| ₹1,757.50 | 34.86 | 4,21,683 Cr | 5.05 | 0.91% | 13.79% | 17.94% | 61,848 Cr | 12,117 Cr | |
| ₹9,558.50 | 86.75 | 2,53,748 Cr | 15.14 | 0.32% | 15.32% | 18.96% | 11,682 Cr | 2,925 Cr | |
| ₹4,557.00 | 71.54 | 1,73,334 Cr | 9.43 | 0.82% | 12.16% | 9.06% | 17,058 Cr | 2,156 Cr | |
| ₹2,181.90 | 107.80 | 1,17,891 Cr | 22.24 | 0.09% | 16.38% | 19.67% | 7,323 Cr | 1,090 Cr | |
| ₹1,175.50 | 26.16 | 1,17,257 Cr | 4.33 | 0.09% | 16.99% | 19.24% | 28,515 Cr | 4,593 Cr | |
| ₹1,335.40 | 34.59 | 1,11,463 Cr | 2.87 | 0.61% | 10.87% | 13.94% | 34,247 Cr | 3,184 Cr | |
| ₹1,365.60 | 32.72 | 1,10,321 Cr | 3.12 | 0.96% | 11.21% | 14.88% | 28,589 Cr | 3,356 Cr | |
| Orchid Pharma (this company) | ₹865.00 | 411.90 | 5,180 Cr | 3.31 | 0.00% | 0.68% | 1.10% | 1,099 Cr | 11 Cr |
| Median 8 companies | ₹1,561.55 | 53.20 | 1,17,574 Cr | 4.69 | 0.47% | 12.98% | 16.41% | 22,787 Cr | 3,055 Cr |
Comparable companies in the same industry. Market cap, P/E and P/B use the live price; other metrics are as reported in filings. A dash means the figure is not published for that company.
Tapetide Score
Data-driven rating, 0–100. How it works →
v2.0.0
Category scores
The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.
Key Insights
Strengths
1- Promoter holding has increased by 4.61% over last quarter.
Weaknesses
5- Stock is trading at 3.02 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
- Tax rate seems low
- Company has a low return on equity of 6.76% over last 3 years.
- Earnings include an other income of Rs.18.6 Cr.
Technical Indicators
Oscillators
Bearish
Overall
Bearish
Moving Averages
Bearish
0 of 1 analyst rates Buy, 1 Hold, 0 Sell.
Updated 28 Oct 2026
Growth Rate
change over 1 year
change over 1 year
change over 1 year
change over 1 year Operating margin 4.6% · Jun 2026
AI Analysis — Bull vs Bear
Orchid Pharma Ltd is a mid-cap pharmaceutical company with a market capitalization of ₹5,031 Cr trading at a PE of 246.7x. While the company has shown a 3-year compounded profit growth of 63% and stock CAGR of 21% over 3 years, TTM sales have declined 12% and TTM profit has fallen 73%, with ROE remaining subdued at around 6% over 3 years.
- Strong 3-year compounded profit growth of 63%, indicating meaningful earnings recovery from a low base
- FY2024 sales reached ₹922 Cr, up 13% year-over-year, and 9M FY25 sales of ₹684 Cr grew 14% vs 9M FY24 (₹602 Cr)
- 9M FY25 EBITDA improved to ₹115 Cr (17% margin) from ₹99 Cr (16% margin) in 9M FY24, showing margin expansion
- Low debt-to-equity ratio of approximately 0.12x, indicating a relatively clean balance sheet post-restructuring
- Stock price CAGR of 38% over 10 years and 21% over 3 years reflects sustained market re-rating
- 5-year compounded sales growth of 13% shows a medium-term revenue expansion trend
- 9M FY25 PBT and PAT improved to ₹78 Cr from ₹62 Cr in 9M FY24, a 26% increase on a year-to-date basis
- PE ratio of 246.7x is extremely elevated, implying the stock prices in significant future growth that may not materialize
- TTM sales declined 12% and TTM profit collapsed 73%, signaling a sharp recent deterioration
- 3-year average ROE of only 6.41% is low for a pharma company trading at 3.94x book value
- Company pays zero dividend despite reporting repeated profits, offering no income return to shareholders
- Earnings quality concern: other income of ₹28.6 Cr forms a significant portion of profits, and company may be capitalizing interest costs
- 10-year compounded sales growth is negative at -1%, reflecting a long history of revenue stagnation
- Q3 FY25 standalone sales of ₹217 Cr declined from ₹221 Cr in Q3 FY24, and EBITDA fell to ₹37 Cr from ₹43 Cr, showing quarterly momentum weakening
- Tax rate appears low, raising questions about the sustainability of reported net profits at current levels
This is AI-generated analysis, not financial advice. Do your own due diligence.
AI News Digest
- Russia licensing deal for Exblifep Jul 7
Orchid Pharma signed a licensing pact with Pharmasyntez JSC for Exblifep in Russia, representing a potential USD 178 million opportunity over 10 years.
- Dhanuka merger effective, share allotment Jul 10
Merger with Dhanuka Laboratories became effective on July 10, 2026 after NCLT order filing. Board meeting scheduled Aug 01 to approve equity share allotment to Dhanuka shareholders.
- Singapore investor roadshow planned Jul 25
Physical investor roadshow in Singapore scheduled for July 29-31, 2026, led by WTD Mridul Dhanuka with no UPSI to be shared.
TL;DR: Orchid Pharma is executing on international expansion with a meaningful USD 178M Russia licensing deal for Exblifep, while completing the Dhanuka Laboratories merger and actively engaging overseas investors. No visible headwinds in recent news flow. The trend is constructive with the company building commercial partnerships and consolidating its corporate structure.
Analyst Forecasts
Analyst consensus here uses a different definition from reported ebitda (they differ 1.7× on periods where both exist), so the forecast is shown on its own rather than joined to the reported line.
Quarterly Results
| Particulars | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 183 | 199 | 221 | 217 | 244 | 223 | 217 | 237 | 263 | 194 | 207 | 368 | 304 |
| Expenses | 161 | 175 | 185 | 188 | 212 | 192 | 191 | 209 | 269 | 195 | 206 | 338 | 290 |
| Operating Profit | 22.14 | 23.3 | 35.38 | 28.91 | 32.49 | 30.34 | 26.37 | 27.99 | -5.65 | -1.47 | 1.56 | 30.16 | 14 |
| OPM % | 12.1% | 11.72% | 16.04% | 13.32% | 13.29% | 13.62% | 12.13% | 11.79% | -2.15% | -0.76% | 0.75% | 8.19% | 4.6% |
| Other Income | 1.89 | 8.36 | 7.62 | 13.36 | 7.57 | 7.52 | 8.49 | 3.9 | 11.57 | 10.77 | -1.5 | 7.55 | 1.83 |
| Interest | 5.55 | 3.8 | 3.54 | 3.47 | 3.5 | 3.33 | 3.8 | 3.92 | 2.28 | 3.73 | 3.18 | 1.96 | 2.23 |
| Depreciation | 7.71 | 7.84 | 9.27 | 8.42 | 8.44 | 8.63 | 8.61 | 8.87 | 10.53 | 8.9 | 9.03 | 10.9 | 10.95 |
| PBT | 10.77 | 20.02 | 30.19 | 30.38 | 28.12 | 25.9 | 22.45 | 19.1 | -6.89 | -3.33 | -12.15 | 24.85 | 2.65 |
| Tax % | 0% | 0% | 0% | -10.27% | -0.53% | 0% | 0% | -0.21% | 0% | 0% | 0% | 0% | 2.64% |
| Net Profit | 9.4 | 19.8 | 29.43 | 32.96 | 29.35 | 27.24 | 20.78 | 22.29 | -5.69 | -5.72 | -12.61 | 25.84 | 3.22 |
| EPS (₹) | 1.85 | 3.9 | 5.8 | 6.5 | 5.79 | 5.37 | 4.1 | 4.39 | -1.12 | -1.13 | -2.49 | 5.09 | 0.63 |
Profit & Loss
| Particulars | Mar 2015 18m | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,747 | 873 | 797 | 683 | 600 | 484 | 450 | 560 | 666 | 819 | 1,398 | 1,233 | 1,073 |
| Expenses | 1,429 | 703 | 794 | 659 | 612 | 515 | 421 | 505 | 581 | 708 | 1,247 | 1,185 | 1,029 |
| Operating Profit | 317 | 171 | 3 | 24 | -12 | -31 | 29 | 55 | 84 | 111 | 151 | 48 | 44 |
| OPM % | 18% | 20% | 0.4% | 3.6% | -2% | -6% | 7% | 10% | 13% | 14% | 11% | 3.9% | 4.1% |
| Other Income | 156 | -28 | -59 | 20 | 218 | 24 | 15 | 67 | 52 | 31 | 26 | 15 | 19 |
| Interest | 537 | 294 | 347 | 310 | 7 | 6 | 52 | 33 | 33 | 17 | 13 | 9 | 11 |
| Depreciation | 325 | 145 | 141 | 133 | 130 | 118 | 109 | 87 | 55 | 33 | 42 | 43 | 40 |
| PBT | -389 | -296 | -544 | -399 | 69 | -131 | -117 | 2 | 48 | 92 | 122 | 10 | 12 |
| Tax % | -49% | -6% | -9% | -12% | 0% | 0% | 0% | 0% | 0% | -3% | -8% | -2% | — |
| Net Profit | -197 | -279 | -495 | -353 | 69 | -131 | -117 | -2 | 46 | 92 | 135 | 10 | 11 |
| EPS (₹) | -23.06 | -31.37 | -55.69 | -39.65 | 7.8 | -32.11 | -28.55 | -0.48 | 11.35 | 18.17 | 26.63 | 1.96 | 2.1 |
| Div. Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | — |
Balance Sheet
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 85 | 89 | 89 | 89 | 89 | 41 | 41 | 41 | 41 | 51 | 15 | 15 |
| Reserves | 244 | -40 | -556 | -881 | -793 | 725 | 612 | 607 | 648 | 1,119 | 1,494 | 1,504 |
| Borrowings | 3,211 | 3,215 | 3,106 | 3,202 | 3,230 | 566 | 453 | 268 | 331 | 135 | 154 | 307 |
| Other Liabilities | 521 | 598 | 616 | 715 | 551 | 128 | 132 | 195 | 205 | 249 | 414 | 432 |
| Total Liabilities | 4,061 | 3,862 | 3,256 | 3,125 | 3,077 | 1,460 | 1,237 | 1,111 | 1,225 | 1,554 | 2,077 | 2,258 |
| Fixed Assets | 1,795 | 1,637 | 1,497 | 1,386 | 1,256 | 858 | 670 | 584 | 573 | 620 | 708 | 692 |
| CWIP | 282 | 280 | 288 | 272 | 278 | 26 | 7 | 10 | 46 | 31 | 81 | 414 |
| Investments | 1 | 1 | 1 | 1 | 0 | 0 | 15 | 45 | 44 | 46 | 60 | 67 |
| Other Assets | 1,984 | 1,944 | 1,470 | 1,467 | 1,542 | 576 | 544 | 472 | 561 | 857 | 1,229 | 1,086 |
| Total Assets | 4,061 | 3,862 | 3,256 | 3,125 | 3,077 | 1,460 | 1,237 | 1,111 | 1,225 | 1,554 | 2,077 | 2,258 |
Cash Flow
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | -369 | 212 | 401 | 9 | 12 | 81 | 24 | 92 | 18 | 126 | 51 | 126 |
| Investing | 1,334 | -1 | -176 | -28 | 45 | 167 | 67 | 113 | -31 | -312 | -36 | -277 |
| Financing | -597 | -286 | -465 | 33 | 0 | -250 | -165 | -217 | 31 | 167 | 2 | 137 |
| Net Cash Flow | 367 | -76 | -240 | 15 | 57 | -2 | -74 | -11 | 18 | -19 | 17 | -14 |
| Free Cash Flow | 965 | 211 | 392 | 3 | 5 | 77 | 23 | 238 | -8 | 61 | -102 | -255 |
| CFO/EBITDA | -102 | 124 | 13,628 | 67 | -138 | -226 | 63 | 173 | 22 | 113 | 44 | 259 |
Ratios
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 54 | 130 | 75 | 64 | 73 | 51 | 110 | 111 | 118 | 87 | 92 | 113 |
| Inventory Days | 118 | 220 | 196 | 202 | 214 | 254 | 244 | 201 | 217 | 199 | 187 | 161 |
| Days Payable | 146 | 341 | 402 | 374 | 381 | 182 | 176 | 195 | 165 | 173 | 137 | 150 |
| Cash Conversion Cycle | 26 | 9 | -130 | -108 | -94 | 123 | 179 | 117 | 170 | 113 | 142 | 124 |
| Working Capital Days | -49 | -168 | -500 | -876 | -1,158 | 166 | 302 | 97 | 54 | 118 | 101 | 105 |
| ROCE % | 1% | 1% | -4% | -4% | -5% | -6% | -5% | -2% | 5% | 9% | 9% | 2% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Orchid Pharma insights
73 extracted metrics + investor summaries across FY12–FY27.
Documents
Frequently Asked Questions about Orchid Pharma
What does Orchid Pharma Ltd do?
Where is Orchid Pharma Ltd (ORCHPHARMA) listed?
Which sector does Orchid Pharma Ltd belong to?
What is the market capitalisation of Orchid Pharma Ltd?
What is the PE ratio of Orchid Pharma Ltd?
What is the 52-week high and low of Orchid Pharma Ltd?
What is the Return on Equity (ROE) of Orchid Pharma Ltd?
Company Information
Orchid Pharma is a pharmaceutical company engaged in the development and manufacture of active pharmaceutical ingredients (APIs) and finished dosage forms. It is also engaged in research of new drugs. [1]
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/ORCHPHARMA.md for Orchid Pharma Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For
live, structured queries instead of documents, use our Indian stock market MCP server.